What type of study is this?

This is a Cohort Study study (also classified as: Validation Study).

What question did this study set out to answer?

The aim is to develop a predictive model for achieving pathological complete response after neoadjuvant therapy in HER2-positive breast cancer.

November 17, 2025Frontiers in OncologyOpen Access

Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response

View Full Paper

Ask AI

Bookmark

Authors

HWHaoqi Wang HWHaoqi Wang SGShan Gao

Discussion

Member takes

Implication

Retrospective analysis assesses treatment efficacy of trastuzumab and pertuzumab in HER2-positive breast cancer, suggesting a nomogram-based prediction model.

Key Points

The aim is to develop a predictive model for achieving pathological complete response after neoadjuvant therapy in HER2-positive breast cancer.
Retrospective analysis of 393 female patients with stage II–III breast cancer
Assessment of ADC values from breast MRI and pathological remission after neoadjuvant therapy
Comparison of efficacy between trastuzumab plus pertuzumab and trastuzumab plus pyrotinib regimens
Construction and internal validation of a predictive nomogram for pCR
Total pathological complete response rate was 68%
No significant difference in tpCR between HP and HPy regimens
HR negativity, HER2 3+, high Ki-67 index, and M-H infiltrating TILs associated with tpCR
Nomogram showed good discrimination (AUC, 0.75) and calibration ability (P = 0.925)

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/692509e8c0ce034ddc352750 https://doi.org/10.3389/fonc.2025.1673810

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis assesses treatment efficacy of trastuzumab and pertuzumab in HER2-positive breast cancer, suggesting a nomogram-based prediction model.

Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response

Discussion

Member takes

Implication

Key Points

Cite This Study

Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider